228 related articles for article (PubMed ID: 12547500)
21. Immunoengineering: how nanotechnology can enhance cancer immunotherapy.
Goldberg MS
Cell; 2015 Apr; 161(2):201-4. PubMed ID: 25860604
[TBL] [Abstract][Full Text] [Related]
22. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
23. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
24. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
25. Synthetic peptides as cancer vaccines.
Sundaram R; Dakappagari NK; Kaumaya PT
Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
[TBL] [Abstract][Full Text] [Related]
26. The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: rethinking anti-tumor vaccines in a new era of cancer immunotherapy.
Signori E; Cavallo F
Cancer Immunol Immunother; 2015 Oct; 64(10):1349-56. PubMed ID: 25762082
[No Abstract] [Full Text] [Related]
27. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
28. Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.
Quatan N; Spicer J; Plunkett T; Pandha H
Clin Oncol (R Coll Radiol); 2004 Aug; 16(5):356-65. PubMed ID: 15341440
[No Abstract] [Full Text] [Related]
29. Recent areas of development for dendritic cell vaccines.
Morse MA; Chui S; Clay TM; Lyerly HK
Cancer Chemother Biol Response Modif; 2003; 21():339-50. PubMed ID: 15338754
[No Abstract] [Full Text] [Related]
30. Dendritic cells: a journey from laboratory to clinic.
Cerundolo V; Hermans IF; Salio M
Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
[No Abstract] [Full Text] [Related]
31. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
32. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
[TBL] [Abstract][Full Text] [Related]
33. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
34. [Tumor vaccines and peptide-loaded dendritic cells (DCs)].
Schummer V; Flindt S; Hinz T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1254-8. PubMed ID: 26349562
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity.
Ressing ME; Offringa R; Toes RE; Ossendorp F; de Jong JH; Brandt RM; Kast WM; Melief CJ
Immunotechnology; 1996 Nov; 2(4):241-51. PubMed ID: 9373306
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
37. Peptide vaccines in cancer-old concept revisited.
Kumai T; Kobayashi H; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Apr; 45():1-7. PubMed ID: 27940327
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell preparation for immunotherapeutic interventions.
Simon T; Fonteneau JF; Grégoire M
Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
[TBL] [Abstract][Full Text] [Related]
39. Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
Morse MA; Clay T; Colling K; Lyerly HK
Mol Biotechnol; 2003 Sep; 25(1):95-9. PubMed ID: 13679640
[TBL] [Abstract][Full Text] [Related]
40. Tumor vaccines in 2010: need for integration.
Koos D; Josephs SF; Alexandrescu DT; Chan RC; Ramos F; Bogin V; Gammill V; Dasanu CA; De Necochea-Campion R; Riordan NH; Carrier E
Cell Immunol; 2010; 263(2):138-47. PubMed ID: 20434139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
